A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
← catalyst calendarSponsored by Immunome, Inc. (industry) · IMNM — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Other
Enrollment
20estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-21 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: Varegacestat Reference Formulation
- Drug: Varegacestat Test Formulation
Primary outcomes
what the primary-completion date above is the date OFEvaluate the rBA of varegacestat by AUC0-t
measured Approximately 3 weeks
Evaluate the rBA of varegacestat by AUC0-inf
measured Approximately 3 weeks
Evaluate the rBA of varegacestat by Cmax
measured Approximately 3 weeks
Permalink · IMNM's whole pipeline · Catalyst calendar · Every registered study · What changed